... [+]This perspective paper underscores the importance of defining longevity biotechnology companies based on their mission to target the fundamental mechanisms of aging. These LBCs aim to develop interventions that not only treat but potentially prevent multiple age-related chronic diseases. As the field grows, clear definitions, rigorous standards, and investor discernment will be pivotal in ensuring its transformative potential in healthcare.
Central to the ethos of an LBC is its commitment to preventing or reversing age-related diseases and extending the healthspan of individuals.
James Peyer of Cambrian Biosciences further elaborates,"A longevity biotech company is one of a new class of biotechs that are developing drugs that target the causes of disease at the cellular level. Processes that break down naturally as we age but could be restored with the right intervention."The realm of longevity biotechnology is vast and varied, with numerous products and interventions touting longevity benefits.
James Peyer further highlights the unique position of LBCs, stating,"LBCs have an important long-term goal not shared by the rest of the biopharma industry, the possibility of using new medicines not just to treat disease, but to keep people healthy. That goal may require different pathways for drug development, different business models, and even different interactions with governments and regulators.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: CNBC - 🏆 12. / 72 Lire la suite »
La source: CNBC - 🏆 12. / 72 Lire la suite »
La source: KUT - 🏆 77. / 68 Lire la suite »